Lexicon Pharmaceuticals Files 8-K on Corporate Changes
Ticker: LXRX · Form: 8-K · Filed: Mar 12, 2024
Sentiment: neutral
Topics: corporate-governance, filing, financials
Related Tickers: LXRX
TL;DR
Lexicon Pharma filed an 8-K today covering corporate changes and financial exhibits.
AI Summary
On March 12, 2024, Lexicon Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, indicating potential corporate governance changes or updates.
Why It Matters
This filing signals potential shifts in Lexicon's corporate structure or security holder rights, which could impact investors and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural and informational, not indicating immediate financial distress or significant negative events.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- March 12, 2024 (date) — Date of earliest event reported
FAQ
What specific material modifications to the rights of security holders are detailed in the filing?
The filing indicates material modifications to the rights of security holders, but the specific details are not provided in the summary information.
Are there any changes to Lexicon Pharmaceuticals' bylaws or articles of incorporation mentioned?
Yes, the filing explicitly states 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item of information.
What is the significance of including 'Financial Statements and Exhibits' in this 8-K filing?
Including financial statements and exhibits suggests that the filing may contain updated financial information or supporting documents related to the corporate changes being reported.
What is the Central Index Key (CIK) for Lexicon Pharmaceuticals?
The Central Index Key for Lexicon Pharmaceuticals, Inc. is 0001062822.
What is the SEC file number for Lexicon Pharmaceuticals?
The SEC file number for Lexicon Pharmaceuticals is 000-30111.
Filing Stats: 756 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-03-12 16:31:00
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 LXRX The Nasdaq Global Select Marke
- $0.01 — Convertible Preferred Stock, par value $0.01 per share (the " Preferred Stock "), th
Filing Documents
- d783185d8k.htm (8-K) — 27KB
- d783185dex31.htm (EX-3.1) — 27KB
- 0001193125-24-065928.txt ( ) — 186KB
- lxrx-20240312.xsd (EX-101.SCH) — 3KB
- lxrx-20240312_lab.xml (EX-101.LAB) — 18KB
- lxrx-20240312_pre.xml (EX-101.PRE) — 11KB
- d783185d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits. Exhibit Number Description 3.1 Certificate of Designations, dated as of March 12, 2024. EX-104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: March 12, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel